All News
ACR Comments on US Healthcare Policy
d
ACR
The American College of Rheumatology (ACR) said it has already joined with hundreds of organizations to submit 26 health policy comment letters to federal officials this year—surpassing the 24 letters the College submitted in 2022.
Read Article
Postural Orthostatic Tachycardia Syndrome Review
The Cleveland Clinic Journal has published a full-read review of postural orthostatic tachycardia syndrome (POTS), a condition often seen in clinic with symptoms like fibromyalgia, but is clinically diagnosed with finding sustained tachycardia upon standing without orthostatic hypotension.
Read Article
Cross-sectional study 365 RA pts showed eating half a pizza >1 time/wk (vs. ≤2 times/mo) was assoc w/ 70% less Dz activity; esp w/ more severe RA (80%) (benefit likely due to mozzarella & olive oil). YES, this was an italian study... https://t.co/6xKMIFdEWf https://t.co/UfpJO1xNe4
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of remote Pt monitoring w/ electronic Outcome Measures (ePROMs) in #RA (4,473 pts, 7 studies) showed lower disease activity & higher remission rates in ePROM group (OR 1.65) & fewer F2F visits were needed in ePROM grp https://t.co/Va2Psx6zSc https://t.co/rdzam3ROJv
Links:
Dr. John Cush RheumNow ( View Tweet)
Antenatal Corticosteroids and Serious Infection in Offspring
A claims data study shows that maternal use of antenatal corticosteroids may be associated with an increased risk of serious infection in the offspring's first 12 months.
https://t.co/0qHgQkQvs9 https://t.co/hv1ACFQSZB
Links:
Dr. John Cush RheumNow ( View Tweet)
Italian JAKi study, 685 pts Rx w/ BARI (48%), TOFA (31%), UPA (14%), filgotinib (7%), had half (47%) Rx JAKi as 1st line, prior to a biologic. AE of special interest (1137 PYs FU) in 18%, including 1 CVA, 3 deaths/infx. High CV risk pts = Hi AESI(23%) https://t.co/0NN60tvokZ https://t.co/Dzc7OG9Mmv
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatology Journals Rife With Faulty Conflict-of-Interest
More often than not, conflict-of-interest disclosures in three major rheumatology journals didn't match records in the U.S. government's Open Payments database, researchers found.
https://t.co/LKyEURZrQY https://t.co/EQLSWXB3o2
Links:
Dr. John Cush RheumNow ( View Tweet)
Mark your calendars! The highly anticipated Association of Women in Rheumatology 2023 conference is just a few weeks away! Don't miss this incredible opportunity to join in virtually for FREE! Register now and secure your spot https://t.co/qqq4c1p6De
Australian Rheumatology Association AusRheum ( View Tweet)
Multi-media, sponsor-generated clinical trial posters presented at major rheumatology meetings are now available in RheumNow’s newest offering: the Poster Hall.
https://t.co/4WRpwh8iRa https://t.co/ZGKDqfjb7Y
Links:
Dr. John Cush RheumNow ( View Tweet)
2023-2024 Best Rheumatology Hospitals
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 6th year in a row they have held this spot.
https://t.co/gGsBr1s0RE https://t.co/Ku6tdzit84
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib in Polymyalgia Rheumatica (EAST PMR Study)
An open-label, uncontrolled pilot trial has shown that JAK signaling is involved in the pathogenesis of PMR and that tofacitinib is as effective as glucocorticoids (GC) in patients with PMR.
https://t.co/XQL7bfkkho https://t.co/HJ2aSIG0rn
Links:
Dr. John Cush RheumNow ( View Tweet)
Spinal CT study of 40 ankylosing spondylitis pts shows the most common site and region of intervertebral fusion were the posterior vertebrae of the middle thoracic region >50% halffused posterior vertebrae Th4–Th5 to Th7–Th8, followed by Cx, last lumbar https://t.co/HzJmpROJmr https://t.co/9qUwlGyBQz
Links:
Dr. John Cush RheumNow ( View Tweet)
High mortality risk predictors in patients with anti-MDA5 dermatomyositis include:
- rapidly progressive interstitial lung disease
- anti-Ro52 antibody
- age > 57 years
(based on study of 126 MDA-5+ DM pts)
https://t.co/JLGIgALUip https://t.co/boTTzrixk9
Links:
Dr. John Cush RheumNow ( View Tweet)
Spanish study of 518 #SLE patients, 7% of whom received at least one dose of rituximab(26) or belimumab (11). RTX given for either hemolytic anemia or ITP (11 pts), nephritis & CNS SLE (5 pts ea). BEL mostlyfor arthritis (8 pts) https://t.co/cgC837Na81 https://t.co/bndKVqNsSE
Links:
Dr. John Cush RheumNow ( View Tweet)
2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease
The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic CPPD disease is unknown.
https://t.co/F0aQR7ZDeU https://t.co/ugXkDmOVML
Links:
Dr. John Cush RheumNow ( View Tweet)
SGLT2 inhibitor (empagliflozin) given in a lupus mouse (MRL/lpr) model showed a renoprotective effect suggesting the value of non-immunosuppressive therapies to improve renal function. Showed less -dsDNA Abs, proteinuria, renal nephritis damage https://t.co/uJjr7rTIJe https://t.co/ptTvwWJlvO
Links:
Dr. John Cush RheumNow ( View Tweet)
Multi-media, sponsor-generated clinical trial posters presented at major rheumatology meetings are now available in RheumNow’s newest offering: the Poster Hall.
https://t.co/YQW2wN9X25 https://t.co/BS9jZRLUo4
Links:
Dr. John Cush RheumNow ( View Tweet)
Composite Measures to Inform Treatment Choices in Bio-naïve Patients with PsA
What is an option for treating and managing bio-naïve patients with PsA?
Dr. Mease and Dr. Khattri discuss.
Therapeutic update sponsored by AbbVie US Medical Affairs.
https://t.co/xha5gyHqor https://t.co/mINKK0ybVD
Links:
Dr. John Cush RheumNow ( View Tweet)
2023-2024 Best Rheumatology Hospitals
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 6th year in a row they have held this spot.
https://t.co/4k6DNJie4n https://t.co/BbPlEFAGH3
Links:
Dr. John Cush RheumNow ( View Tweet)
Paradoxical Rxns (PR) & biologics in TReasure database: 2867 RA & 5316 SpA pts; 5-yr FUV found 136 pts (1.7%) developed the PRs; 60% w/ 1st biologic, after median 12 mos, 93% psoriais (pustular 60%, palmoplantar 31%), many better w/ another TNFi https://t.co/5tybXZZVKW https://t.co/1nQaXQOEDD
Links:
Dr. John Cush RheumNow ( View Tweet)